Clinical development and trial testing of vesleteplirsen (SRP-5051) for Duchenne muscular dystrophy (DMD) was stopped, with ...

As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. The accrual ratio subtracts the FCF ...

Investors consider Dyne Therapeutics' treatments for muscle diseases and strong cash position as a speculative Buy ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Sarepta Therapeutics (SRPT – Research Report) and DocGo (DCGO – Research Report) with bullish sentiments.

Sarepta Therapeutics (Nasdaq: SRPT) has announced it will cease development of SRP-5051, an experimental drug for Duchenne ...

Sarepta Therapeutics is advancing SRP-9003 gene therapy for LGMD, with phase 3 study results expected in early 2025. Learn ...

Mizuho Securities analyst Uy Ear has maintained their bullish stance on SRPT stock, giving a Buy rating today. Uy Ear’s rating is based on several positive developments for Sarepta Therapeutics. The ...

Baird lowered the firm’s price target on Sarepta (SRPT) to $193 from $200 and keeps an Outperform rating on the shares. The firm said Elevidys sales showed better-than-expected growth in 3Q with ...